NovaGo is advancing the development of its lead drug candidate, NG004, through preclinical and early clinical phases for the treatment of spinal cord injury. Novago collaborates with Neurimmune AG on the research and development of anti-Nogo-A antibodies.

We are interested in partnerships with organizations that provide complimentary expertise and resources to maximize the commercial value of our drug candidates. For further information on investment or partnering opportunities, please contact us at: info@novagotherapeutics.com